Literature DB >> 1345765

Presynaptic glutamate receptors regulate noradrenaline release from isolated nerve terminals.

J K Wang1, H Andrews, V Thukral.   

Abstract

The wide-ranging neuronal actions of excitatory amino acids, such as glutamate, are thought to be mediated mainly by postsynaptic N-methyl-D-aspartate (NMDA) and non-NMDA receptors. We now report the existence of presynaptic glutamate receptors in isolated nerve terminals (synaptosomes) prepared from hippocampus, olfactory bulb, and cerebral cortex. Activation of these receptors by NMDA or non-NMDA agonists, in a concentration-dependent manner, resulted in Ca(2+)-dependent release of noradrenaline from vesicular transmitter stores. The NMDA-stimulated release was potentiated by glycine and was blocked by Mg2+ and selective NMDA antagonists. In contrast, release stimulated by selective non-NMDA agonists was blocked by 6-cyano-7-nitroquinoxaline-2,3- dione, but not by Mg2+ or NMDA antagonists. Our data suggest that the presynaptic glutamate receptors can be classified pharmacologically as both the NMDA and non-NMDA types. These receptors, localized on nerve terminals of the locus ceruleus noradrenergic neurons, may play an important role in interactions between noradrenaline and glutamate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345765     DOI: 10.1111/j.1471-4159.1992.tb09297.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Ornithine decarboxylase activity in cerebral post-ischemic reperfusion damage: effect of methionine sulfoximine.

Authors:  C Di Giacomo; V Sorrenti; R Acquaviva; A Campisi; G Vanella; J R Perez-Polo; A Vanella
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

3.  Presynaptic effects of NMDA in cerebellar Purkinje cells and interneurons.

Authors:  M Glitsch; A Marty
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

4.  Action of 5-hydroxytryptamine in facilitating N-methyl-D-aspartate depolarization of cortical neurones mimicked by calcimycin, cyclopiazonic acid and thapsigargin.

Authors:  S Rahman; R S Neuman
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

5.  Immuno-Pharmacological Characterization of Presynaptic GluN3A-Containing NMDA Autoreceptors: Relevance to Anti-NMDA Receptor Autoimmune Diseases.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Cesare Usai; Anna Pittaluga
Journal:  Mol Neurobiol       Date:  2019-02-07       Impact factor: 5.590

6.  Effect of nicotine on the level of extracellular amino acids in the hippocampus of rat.

Authors:  E Toth
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

7.  NMDA and AMPA receptors evoke transmitter release from noradrenergic axon terminals in the rat spinal cord.

Authors:  E Sundström; L Holmberg; F Souverbie
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

8.  Regulation of N-methyl-D-aspartate receptor-mediated calcium transport and norepinephrine release in rat hippocampus synaptosomes by polyamines.

Authors:  F Siddiqui; Z Iqbal
Journal:  Neurochem Res       Date:  1994-11       Impact factor: 3.996

9.  Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test.

Authors:  Todd D Gould; Kelley C O'Donnell; Eliot R Dow; Jing Du; Guang Chen; Husseini K Manji
Journal:  Neuropharmacology       Date:  2007-11-17       Impact factor: 5.250

10.  Ionotropic glutamate receptor types leading to adenosine-mediated inhibition of electrically evoked [3H]-noradrenaline release in rabbit brain cortex slices.

Authors:  I von Kügelgen; L Späth; K Starke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.